广济药业(000952) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥180,917,718.37, a decrease of 26.11% compared to ¥244,847,193.28 in the same period last year[8] - Net profit attributable to shareholders was ¥30,418,048.31, down 64.16% from ¥84,870,728.18 year-on-year[8] - The net cash flow from operating activities was ¥7,119,509.04, representing a decline of 73.77% compared to ¥27,145,653.23 in the previous year[8] - Basic earnings per share decreased by 63.80% to ¥0.122 from ¥0.337 in the same period last year[8] - The company's operating revenue for Q1 was $180.92 million, a decrease of 26.11% compared to $244.85 million in the same period last year[15] - Net profit fell by 65.66% to $29.85 million from $86.94 million in the previous year[15] - The company's earnings per share decreased by 63.80% to $0.122 from $0.337 year-over-year[15] - The total comprehensive income attributable to the parent company was CNY 30,402,712.89, compared to CNY 84,870,728.18 in the previous period[47] - The total comprehensive income for the quarter was CNY 29,836,796.11, compared to CNY 86,937,075.93 in the previous period[47] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,795,304,345.00, an increase of 6.02% from ¥1,693,288,037.08 at the end of the previous year[8] - The company's total liabilities reached CNY 884,509,353.82, up from CNY 812,329,842.01, reflecting an increase of approximately 8.9%[34] - Current assets totaled CNY 539.35 million, an increase of 16.1% from CNY 464.47 million at the end of 2018[38] - The company's total liabilities amounted to CNY 913.32 million, an increase of 6.0% from CNY 860.92 million at the end of 2018[39] - The company's cash and cash equivalents increased to CNY 257,403,161.07 from CNY 173,552,396.73, reflecting a growth of approximately 48.4%[32] - The total assets of the company as of January 1, 2019, were CNY 1,693,288,037.08, with total liabilities of CNY 812,329,842.01[60] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,005[11] - The company initiated a share buyback program, repurchasing 2,995,100 shares, which is 1.19% of its total share capital, to enhance shareholder value[21] - The company plans to use the repurchased shares for converting into convertible bonds, ensuring shareholder value and confidence[22] Government and Regulatory Matters - The company received government subsidies amounting to ¥1,600,235.70 during the reporting period[9] - The company plans to conduct a non-public offering of shares, pending approval from the China Securities Regulatory Commission[19] Operational Metrics - Operating costs increased by 22.07% to $91.94 million from $75.32 million year-over-year[15] - The company reported a significant increase in net cash flow from financing activities, rising by 517.77% to $90.74 million from -$21.72 million year-over-year[15] - The company reported a decrease in research and development expenses to CNY 9.24 million, down 10.8% from CNY 10.36 million in the previous year[41] - The company incurred a net cash outflow from investment activities of CNY 12,222,221.92, indicating ongoing investments in fixed assets and other long-term assets[56] Inventory and Receivables - Inventory levels increased to CNY 122,803,661.99 from CNY 98,486,134.87, representing a growth of approximately 24.7%[32] - Accounts receivable rose to CNY 138,511,869.92 from CNY 133,497,778.60, indicating a slight increase of about 3.1%[32] - Inventory rose to CNY 83.33 million, a significant increase of 51.5% compared to CNY 55.03 million at the end of 2018[38] Cash Flow - The cash flow from operating activities generated a net amount of CNY 7,119,509.04, a significant decrease from CNY 27,145,653.23 in the previous year[51] - The net cash flow from operating activities for the first quarter was CNY 24,669,176.18, a decrease of 47.3% compared to CNY 46,765,335.63 in the previous year[55] - Total cash inflow from financing activities amounted to CNY 166,664,982.81, while cash outflow was CNY 75,927,402.28, resulting in a net cash flow of CNY 90,737,580.53[56] - The company reported a net increase in cash and cash equivalents of CNY 83,850,764.34, compared to a decrease of CNY 10,960,899.57 in the same period last year[52] Compliance and Certification - The company received the GMP certification for its production lines, ensuring compliance with quality management standards[17] - The company has not audited the first quarter report, indicating a lack of external verification for the reported figures[64]